These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32162714)

  • 1. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
    Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Kim S; Li L; Zhang J; Jiang C; Lü J
    Prostate; 2022 Jan; 82(1):154-166. PubMed ID: 34662447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
    Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
    Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
    Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
    Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN-knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid.
    Wang L; Wang C; Sarwar MS; Chou P; Wang Y; Su X; Kong AT
    FASEB J; 2022 Nov; 36(11):e22626. PubMed ID: 36305462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer.
    Wang C; Feng Y; Zhang C; Cheng D; Wu R; Yang Y; Sargsyan D; Kumar D; Kong AN
    FASEB J; 2020 Jan; 34(1):1304-1318. PubMed ID: 31914691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
    Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
    Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
    Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.
    Takahara K; Ibuki N; Ghaffari M; Tearle H; Ong CJ; Azuma H; Gleave ME; Pollak M; Cox ME
    Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):239-47. PubMed ID: 23689346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
    J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
    Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate.
    Desai KV; Michalowska AM; Kondaiah P; Ward JM; Shih JH; Green JE
    Mol Endocrinol; 2004 Dec; 18(12):2895-907. PubMed ID: 15358834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
    Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
    Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
    Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
    Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.
    Korsten H; Ziel-van der Made AC; van Weerden WM; van der Kwast T; Trapman J; Van Duijn PW
    PLoS One; 2016; 11(1):e0147500. PubMed ID: 26807730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.